Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive - PubMed (original) (raw)

. 2006 Feb;13(2):289-300.

doi: 10.1016/j.ymthe.2005.09.015. Epub 2005 Nov 7.

Affiliations

• PMID: 16275099
• DOI: 10.1016/j.ymthe.2005.09.015

Free article

Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive

Seon Hee Kim et al. Mol Ther. 2006 Feb.

Free article

Abstract

We previously have demonstrated the ability of primary murine bone marrow-derived DC (BM-DC), genetically modified by adenoviral infection to express FasL, to inhibit progression of established collagen-induced arthritis (CIA) following systemic delivery. Here we demonstrate that exosomes derived from genetically modified BM-DC expressing FasL are able to inhibit inflammation in a murine footpad model of delayed-type hypersensitivity (DTH). Local administration of exosomes derived from DC expressing FasL (Exo/FasL) as well as the parental DC/FasL resulted in a significant reduction in swelling in both the treated and the untreated distal paw. However, both the DC/FasL and the Exo/FasL were unable to suppress the DTH response in lpr (Fas-deficient) mice. Gene transfer of FasL to BM-DC from gld (FasL-deficient) mice resulted in restoration of the ability of DC as well as DC-derived exosomes to suppress DTH. The ability of DC-derived exosomes and DC to suppress DTH responses was antigen specific and MHC class II dependent, but class I independent. The injected exosomes were found to be internalized into CD11c(+) cells at the site of injection and in the draining popliteal lymph node. Systemic injection of exosome/FasL into mice with established CIA resulted in significant disease amelioration. These results demonstrate that both systemic and local administration of exosomes derived from FasL-expressing DC are able to suppress antigen-specific immune responses through an MHC class II-dependent pathway, resulting in effective and sustained treatment of established collagen-induced arthritis and suppression of the DTH inflammatory response. These results suggest that DC/FasL-derived exosomes could be used clinically for the treatment of inflammatory and autoimmune diseases.

PubMed Disclaimer

Similar articles

• Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis.
  Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD. Kim SH, et al. J Immunol. 2005 May 15;174(10):6440-8. doi: 10.4049/jimmunol.174.10.6440. J Immunol. 2005. PMID: 15879146
• Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4.
  Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD. Kim SH, et al. J Immunol. 2007 Aug 15;179(4):2242-9. doi: 10.4049/jimmunol.179.4.2242. J Immunol. 2007. PMID: 17675485
• Modulation of the immune response using dendritic cell-derived exosomes.
  Bianco NR, Kim SH, Morelli AE, Robbins PD. Bianco NR, et al. Methods Mol Biol. 2007;380:443-55. doi: 10.1007/978-1-59745-395-0_28. Methods Mol Biol. 2007. PMID: 17876111 Review.
• Dendritic cells transduced with viral interleukin 10 or Fas ligand: no evidence for induction of allotolerance in vivo.
  Buonocore S, Van Meirvenne S, Demoor FX, Paulart F, Thielemans K, Goldman M, Flamand V. Buonocore S, et al. Transplantation. 2002 Jan 15;73(1 Suppl):S27-30. doi: 10.1097/00007890-200201151-00010. Transplantation. 2002. PMID: 11810058 Review.

Cited by

• Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth.
  Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O. Mizrak A, et al. Mol Ther. 2013 Jan;21(1):101-8. doi: 10.1038/mt.2012.161. Epub 2012 Aug 21. Mol Ther. 2013. PMID: 22910294 Free PMC article.
• Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions.
  Zhang HG, Grizzle WE. Zhang HG, et al. Am J Pathol. 2014 Jan;184(1):28-41. doi: 10.1016/j.ajpath.2013.09.027. Epub 2013 Nov 21. Am J Pathol. 2014. PMID: 24269592 Free PMC article. Review.
• Nanomedicine: evolutionary and revolutionary developments in the treatment of certain inflammatory diseases.
  Szelenyi I. Szelenyi I. Inflamm Res. 2012 Jan;61(1):1-9. doi: 10.1007/s00011-011-0393-7. Epub 2011 Nov 5. Inflamm Res. 2012. PMID: 22057873 Review.
• Proteomic and immunologic analyses of brain tumor exosomes.
  Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Graner MW, et al. FASEB J. 2009 May;23(5):1541-57. doi: 10.1096/fj.08-122184. Epub 2008 Dec 24. FASEB J. 2009. PMID: 19109410 Free PMC article.
• Biological gene delivery vehicles: beyond viral vectors.
  Seow Y, Wood MJ. Seow Y, et al. Mol Ther. 2009 May;17(5):767-77. doi: 10.1038/mt.2009.41. Epub 2009 Mar 10. Mol Ther. 2009. PMID: 19277019 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal